DuPont de Nemours recently released its latest 10-Q report. The company describes itself as a provider of technology-based materials and solutions across healthcare, water, construction, and industrial markets, with operations in the United States, Canada, Asia Pacific, Latin America, Europe, the Middle East and Africa. It reports through two segments, Healthcare & Water Technologies and Diversified Industrials, and its portfolio includes TYVEK, AMBERLITE, FILMTEC, INGE, ITEGRATEC, STYROFOAM, CORIAN, Vespel, MOLYKOTE, BETAFORCE, BETASEAL and Cyrel.
In management’s discussion and analysis, DuPont said it had $2.9 billion of working capital and about $1.7 billion of cash and cash equivalents at June 30, 2026. The company said it expects cash on hand, cash from operations and access to debt markets to cover liquidity needs tied to continuing operations.
DuPont’s recent transaction activity has materially reshaped the company. On April 1, 2026, it completed the sale of its Aramids business to Arclin, receiving about $1.2 billion of pre-tax cash proceeds, a $300 million note receivable and a non-controlling equity interest valued at $325 million. The Aramids results are now reported as discontinued operations. Earlier, on Nov. 1, 2025, DuPont completed the separation of its semiconductor and interconnect solutions businesses into Qnity Electronics, and those results are also shown as discontinued operations for all periods.
The company also executed a 1-for-3 reverse stock split effective June 24, 2026. DuPont declared a second-quarter dividend of $0.60 per share, paid May 29, 2026, and a third-quarter dividend of $0.60 per share payable Sept. 15, 2026.
For the second quarter, net sales rose to $1.819 billion from $1.749 billion a year earlier, up 4 percent. For the first six months, sales increased to $3.500 billion from $3.361 billion, also up 4 percent. The company attributed the quarterly increase to 4 percent organic growth, with Healthcare & Water Technologies up 4 percent and Diversified Industrials up 3 percent. For the six-month period, organic sales rose 3 percent and currency added 1 percent, with the euro’s weakness against the dollar cited as the main driver.
Cost of sales was $1.2 billion in the quarter, about flat as a percentage of sales at 65 percent, and $2.3 billion for the first half, equal to 65 percent of sales versus 66 percent a year earlier. R&D spending fell to $42 million from $53 million in the quarter and to $89 million from $103 million in the half. SG&A was $269 million in the quarter, up from $262 million, and $524 million in the half, up from $496 million.
Amortization of intangibles declined to $68 million in the quarter from $74 million and to $136 million in the half from $149 million, reflecting the absence of amortization from fully amortized assets. DuPont recorded $3 million of net restructuring benefits in the quarter and $43 million of net restructuring charges in the first half, tied mainly to the 2026 DuPont Restructuring Program. Acquisition, integration and separation costs were $7 million in both the quarter and half, down sharply from $55 million and $105 million a year earlier, when the company was preparing for the Electronics Separation and Aramids Divestiture.
Interest expense dropped to $41 million in the quarter from $84 million and to $81 million in the half from $167 million, mainly because of capital structure changes in 2025 tied to the Electronics Separation. The effective tax rate on continuing operations fell to 28.2 percent in the quarter from 69.2 percent and to 23.7 percent in the half from 40.6 percent, with 2025 transaction-related items driving the difference. Today the company's shares have moved -2.63% to a price of $137.57. If you want to know more, read the company's complete 10-Q report here.
